Vyndaqel and Memory loss - a phase IV clinical study of FDA data

Summary:

Memory loss is reported as a side effect among people who take Vyndaqel (tafamidis meglumine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Vitamin D3, and have Amyloidosis.

The phase IV clinical study analyzes which people have Memory loss when taking Vyndaqel. It is created by eHealthMe based on reports of 3,783 people who have side effects when taking Vyndaqel from the FDA, and is updated regularly.

What is Vyndaqel?

Vyndaqel has active ingredients of tafamidis meglumine. eHealthMe is studying from 3,783 Vyndaqel users. Check the latest studies of Vyndaqel.

What is Memory loss?

Memory loss is found to be associated with 2,728 drugs and 4,375 conditions by eHealthMe. Check the latest studies of Memory loss.

On Jul, 17, 2026

3,783 people reported to have side effects when taking Vyndaqel.
Among them, 50 people (1.32%) have Memory loss.

Among these 50 people:

How long have people been on Vyndaqel when they have Memory loss? *

What is the gender of people who have Memory loss when taking Vyndaqel? *

female: 22 %
male: 78 %

What is the age of people who have Memory loss when taking Vyndaqel? *

What are other drugs people take besides Vyndaqel? *

What are other side effects people have besides Memory loss? *

Fatigue (feeling of tiredness): 17 people, 34.00%
Hypoacusis (loss of hearing): 16 people, 32.00%
Gait Disturbance: 15 people, 30.00%
Nephropathy (damage to or disease of a kidney): 14 people, 28.00%
Weight Decreased: 14 people, 28.00%
Drowsiness: 13 people, 26.00%
Tachyphrenia (abnormally rapid mental activity): 12 people, 24.00%
Feeling Abnormal: 12 people, 24.00%
Back Pain: 12 people, 24.00%
Tooth Abscess (pus formation in tooth): 12 people, 24.00%

What are the existing conditions these people have? *

Amyloidosis (a tumour within which amyloid is produced): 29 people, 58.00%
Cardiac Amyloidosis (protein deposition in heart): 19 people, 38.00%
Cardiac Failure Congestive: 12 people, 24.00%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 12 people, 24.00%
Pain: 12 people, 24.00%
Atherosclerosis (disorder of the arteries): 12 people, 24.00%
Blood Pressure Abnormal: 12 people, 24.00%
Vitamin D Decreased: 12 people, 24.00%
High Blood Pressure: 10 people, 20.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 10 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Vyndaqel and have Memory loss?

- Check whether Memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vyndaqel:

Vyndaqel (3,783 reports)

Memory loss treatments and more:

Memory loss (244,444 reports)

Browse all side effects of Vyndaqel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Memory loss:

Memory loss (2,728 drugs)

Browse all the conditions that are associated with Memory loss:

Memory loss (4,375 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tafamidis meglumine (the active ingredients of Vyndaqel) and Vyndaqel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.